Rani E. George, MD, PhD

Rani E. George, MD, PhD

Pediatric Hematology/Oncology

Contact Information

Fax

617-632-4850

Appointments

888-733-4662 (New Pediatric Patients)
617-632-3270 (Established Pediatric Patients)

Biography

Rani E. George, MD, PhD

Dr George received her MD from the University of Liberia and her PhD from the University of Newcastle-upon-Tyne, UK. She completed clinical training in pediatrics and hematology/oncology at the Royal Victoria Infirmary, Newcastle-upon-Tyne, Boston Children's Hospital and Dana-Farber Cancer Institute. She conducted post-doctoral research at Harvard Medical School and Dana-Farber. Her laboratory focuses on identifying molecular targets in cancer cells that can be translated into novel therapies with special emphasis on the pediatric solid tumor neuroblastoma. The translational research program in her laboratory integrates cancer biology, preclinical drug development and clinical trials targeting molecular aberrations in neuroblastoma and other pediatric solid tumors.

Board Certification

  • Pediatric Hematology/Oncology

Fellowship

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology
  • Harvard Medical School, Pathology

Residency

  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics
  • The Royal Victoria Infirmary

Medical School

  • A. M. Dogliotti College of Medicine, University of Liberia

Publications

    • Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. J Immunother Cancer. 2022 12; 10(12). View in: Pubmed

    • Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nat Cancer. 2022 10; 3(10):1228-1246. View in: Pubmed

    • Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Front Oncol. 2021; 11:773186. View in: Pubmed

    • Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. Cell Rep. 2021 07 13; 36(2):109363. View in: Pubmed

    • Giotto: a toolbox for integrative analysis and visualization of spatial expression data. Genome Biol. 2021 03 08; 22(1):78. View in: Pubmed

    • Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020 09; 136:52-68. View in: Pubmed

    • Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cell Stem Cell. 2020 04 02; 26(4):579-592.e6. View in: Pubmed

    • MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nat Commun. 2020 02 14; 11(1):913. View in: Pubmed

    • Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. Nat Commun. 2019 12 20; 10(1):5806. View in: Pubmed

    • Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. J Clin Invest. 2019 10 01; 129(10):4377-4392. View in: Pubmed

    • BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature. 2019 08; 572(7771):676-680. View in: Pubmed

    • JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nat Commun. 2019 07 25; 10(1):3319. View in: Pubmed

    • CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019 04 15; 10(1):1757. View in: Pubmed

    • mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018 09; 561(7724):556-560. View in: Pubmed

    • Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). J Med Chem. 2018 05 10; 61(9):4249-4255. View in: Pubmed

    • Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell Chem Biol. 2018 02 15; 25(2):135-142.e5. View in: Pubmed

    • Super-Enhancer-Driven Transcriptional Dependencies in Cancer. Trends Cancer. 2017 04; 3(4):269-281. View in: Pubmed

    • Cbx3/HP1? deficiency confers enhanced tumor-killing capacity on CD8+ T cells. Sci Rep. 2017 02 21; 7:42888. View in: Pubmed

    • Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Mol Oncol. 2016 06; 10(6):866-78. View in: Pubmed

    • Targeting ALK: The Ten Lives of a Tumor. Cancer Discov. 2016 Jan; 6(1):20-1. View in: Pubmed

    • Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. J Med Chem. 2015 Dec 10; 58(23):9296-9308. View in: Pubmed

    • TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015 Dec; 47(12):1411-4. View in: Pubmed

    • Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations. Clin Cancer Res. 2015 Nov 01; 21(21):4747-9. View in: Pubmed

    • A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015 Oct; 64(10):1251-60. View in: Pubmed

    • Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014 Dec 08; 26(6):909-922. View in: Pubmed

    • CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014 Nov 20; 159(5):1126-1139. View in: Pubmed

    • Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014 Sep 30; 5(18):8737-49. View in: Pubmed

    • Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. PLoS One. 2014; 9(3):e92886. View in: Pubmed

    • Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. PLoS Genet. 2013 Jun; 9(6):e1003533. View in: Pubmed

    • The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012 Jul 10; 22(1):117-30. View in: Pubmed

    • Promising therapeutic targets in neuroblastoma. Clin Cancer Res. 2012 May 15; 18(10):2740-53. View in: Pubmed

    • Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012 Mar 20; 21(3):362-73. View in: Pubmed

    • Tumor histology during induction therapy in patients with high-risk neuroblastoma. Pediatr Blood Cancer. 2012 Sep; 59(3):506-10. View in: Pubmed

    • Emerging importance of ALK in neuroblastoma. Semin Cancer Biol. 2011 Oct; 21(4):267-75. View in: Pubmed

    • Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. ACS Med Chem Lett. 2011 May 12; 2(5):379-384. View in: Pubmed

    • Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer. 2010 Oct 15; 9:277. View in: Pubmed

    • Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Oct; 55(4):629-38. View in: Pubmed

    • Pharmacotherapy of neuroblastoma. Expert Opin Pharmacother. 2010 Jun; 11(9):1467-78. View in: Pubmed

    • Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009 May 15; 69(10):4143-9. View in: Pubmed

    • Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009 Mar; 9(3):331-56. View in: Pubmed

    • Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215):975-8. View in: Pubmed

    • The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93. View in: Pubmed

    • Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res. 2007 Dec 01; 67(23):11234-43. View in: Pubmed

    • Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One. 2007 Feb 28; 2(2):e255. View in: Pubmed

    • Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res. 2006 Oct 01; 12(19):5693-7. View in: Pubmed

    • High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006 Jun 20; 24(18):2891-6. View in: Pubmed

    • Zebrafish foxd3 is selectively required for neural crest specification, migration and survival. Dev Biol. 2006 Apr 01; 292(1):174-88. View in: Pubmed

    • Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005 Sep 20; 23(27):6466-73. View in: Pubmed

    • Association between congenital cardiovascular malformations and neuroblastoma. J Pediatr. 2004 Apr; 144(4):444-8. View in: Pubmed

    • Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res. 2003 Aug 15; 9(9):3338-44. View in: Pubmed

    Locations

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Dana 640E Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Dana 640E Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Rani E. George, MD, PhD

    About Our Ratings

    Physician Star Rating Comment Block